This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hölschermann, H. Articles by Haberbosch, W. Search for Related Content PubMed PubMed Citation Articles by Hölschermann, H. Articles by Haberbosch, W. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Coronary Artery Disease Heart Transplantation Related Collections Coagulation and fibronolysis Transplantation

(Circulation. 2000;102:357.)
© 2000 American Heart Association, Inc.

Basic Science Reports

Hirudin Reduces Tissue Factor Expression and Attenuates Graft Arteriosclerosis in Rat Cardiac Allografts

Hans Hölschermann, MD; Rainer M. Bohle, MD; Heiko Schmidt, MD; Hagen Zeller, MD; Ludger Fink, MD; Ulrich Stahl, MD; Helmut Grimm, MD; Harald Tillmanns, MD; Werner Haberbosch, MD

From the Departments of Internal Medicine (H.H., H.S., H.Z., H.T., W.H.), Pathology (R.M.B., L.F., U.S.), and General and Thoracic Surgery (H.G.), Justus-Liebig-University, Giessen, Germany.

Correspondence to Dr Hans Hölschermann, Department of Internal Medicine, Division of Cardiology, University of Giessen, Klinikstraße 36, D-35392 Giessen, Germany. E-mail hans.f.hoelschermann{at}innere.med.uni-giessen.de

Background—Intravascular clotting has been implicated in the pathogenesis of cardiac allograft vasculopathy (CAV). We previously identified the expression of tissue factor (TF), the primary cellular initiator of blood coagulation, within the coronary intima, which was associated with neointimal thickening. In the present study, the effect of recombinant hirudin on CAV was assessed in Lewis to Fisher rat heterotopic cardiac allografts.

Methods and Results—Transplant recipients were randomized to a control group (n=10) and a hirudin-treated group (n=12; 2 mg · kg^-1 · d^-1 SC). Histological evaluations of rejection, CAV, and TF staining were performed 120 days after transplantation. No significant differences were observed between the 2 groups with respect to the degree of rejection. Hirudin significantly (P<0.05) suppressed the development of CAV in the graft microvessels, but it was less effective in large coronary arteries. Graft intimal cells, isolated by laser-assisted cell picking, showed a marked upregulation of TF gene transcription, which was prevented by hirudin (P<0.01). As demonstrated by immunohistochemistry and quantitative analyses of TF mRNA levels by real-time polymerase chain reaction, hirudin treatment resulted in a significant reduction of TF protein and mRNA expression (P<0.001).

Conclusions—Treatment with hirudin in this rat cardiac transplant model inhibited TF expression and decreased neointimal hyperplasia. These results suggest that TF inhibition by hirudin, in addition to its direct effect on thrombin, may attenuate the hypercoagulable state and prevent the development of CAV at least in restricted sites of the graft coronary vasculature.

Key Words: transplantation • hirudin • arteriosclerosis

This article has been cited by other articles:

				B. Wootla, A. Nicoletti, N. Patey, J. D. Dimitrov, C. Legendre, O. D. Christophe, A. Friboulet, S. V. Kaveri, S. Lacroix-Desmazes, and O. Thaunat Hydrolysis of Coagulation Factors by Circulating IgG Is Associated with a Reduced Risk for Chronic Allograft Nephropathy in Renal Transplanted Patients J. Immunol., June 15, 2008; 180(12): 8455 - 8460. [Abstract] [Full Text] [PDF]

				D. Chen, J. M. Abrahams, L. M. Smith, J. H. McVey, R. I. Lechler, and A. Dorling Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors Blood, April 15, 2008; 111(8): 4155 - 4164. [Abstract] [Full Text] [PDF]

				A. Zhang, X. Liu, J. G. Cogan, M. D. Fuerst, J. A. Polikandriotis, R. J. Kelm Jr., and A. R. Strauch YB-1 Coordinates Vascular Smooth Muscle {alpha}-Actin Gene Activation by Transforming Growth Factor {beta}1 and Thrombin during Differentiation of Human Pulmonary Myofibroblasts Mol. Biol. Cell, October 1, 2005; 16(10): 4931 - 4940. [Abstract] [Full Text] [PDF]

				H. Shimizu, M. Takahashi, T. Kaneko, T. Murakami, Y. Hakamata, S. Kudou, T. Kishi, K. Fukuchi, S. Iwanami, K. Kuriyama, et al. KRP-203, a Novel Synthetic Immunosuppressant, Prolongs Graft Survival and Attenuates Chronic Rejection in Rat Skin and Heart Allografts Circulation, January 18, 2005; 111(2): 222 - 229. [Abstract] [Full Text] [PDF]

				M. H. Yen, G. Pilkington, R. C. Starling, N. B. Ratliff, P. M. McCarthy, J. B. Young, G. M. Chisolm, and M. S. Penn Increased Tissue Factor Expression Predicts Development of Cardiac Allograft Vasculopathy Circulation, September 10, 2002; 106(11): 1379 - 1383. [Abstract] [Full Text] [PDF]

				L. Fink, S. Kohlhoff, M. M. Stein, J. Hanze, N. Weissmann, F. Rose, E. Akkayagil, D. Manz, F. Grimminger, W. Seeger, et al. cDNA Array Hybridization after Laser-Assisted Microdissection from Nonneoplastic Tissue Am. J. Pathol., January 1, 2002; 160(1): 81 - 90. [Abstract] [Full Text] [PDF]